Contribution
My Lords, from the comments by my noble colleagues, I assume that everyone supports the instrument in front of us. It is clear that our approach has to balance regulatory compliance, environmental responsibility and the practical realities faced by industry across the UK. The noble Lord asked about much of those practical impacts. Our actions are guided not only by the domestic priorities but by our international commitments under the Stockholm convention and the evolving expectations of our global partners.
The noble Lord, Lord Roborough, asked about the EU and the agreements that we are currently finishing negotiations on. This is an international commitment under the Stockholm convention; it is not tied to the negotiations with the EU. The legislation ensures that existing legal provisions for the prohibition and restriction of the manufacture, use and placing on the market of POPs will be extended to the newest POP substances that have been adopted for global elimination under the Stockholm convention. The reason for doing that is to continue to protect the current and future health of the population, wildlife and environment of both the United Kingdom and the rest of the world. We will also amend the legal provisions on the two existing POPs, as I mentioned, to adapt them to scientific and technical progress.
The impact assessment, which has been referenced, clearly demonstrates that the changes are going to maintain a high level of protection for human health and the environment. At the same time, to come back to the noble Lord’s question about costs to industry, it is to avoid any unnecessary costs to industry, because that is really important. That is partly why we have the exemptions and the transition periods. The chemical sector is one of the United Kingdom’s most important manufacturing industries. Its products are essential to sectors right across the economy and to many aspects of our daily lives. We fully recognise the economic and strategic importance, but at the same time we have to recognise risks to human health and the environment if chemicals are not properly understood and managed. The instrument is designed to strike the right and appropriate balance here, preserving strong environmental and health protections while at the same time providing industry with the time and certainty that it is going to need to transition over to the safer alternative substances.
I come to a few of the specific questions. My noble friend Lord Stansgate asked about new nominations and the timings for those. Clearly, if there are serious concerns about a chemical, we need to act as quickly as we possibly can. As a party to the Stockholm convention, we engage with its substance evaluation process via the POPs Review Committee and meetings of the Conference of the Parties, in addition to online correspondence. All relevant stakeholders have opportunities to put into the convention process through the calls for comments and information that we hold on the GOV.UK website. We currently have a live call for information on the three substances being considered for adoption by the committee; that is happening right now. We encourage stakeholders to submit information, as we need to be really robust. We need timely information to inform the international discussions taking place right now, so that we can move forward as quickly as we can under the circumstances.
The noble Baroness, Lady Redfern, asked about consultation and the concerns of industry and business. A draft of the instrument was published as part of the statutory public consultation in spring this year. It sought feedback on our proposed approach to the prohibitions, on our intention to implement all the exemptions allowed for under the Stockholm convention and on equivalent amendments or proposals, including any potential impacts of divergence with the EU. It was shared widely with industry, including through other relevant departments and trade associations, so that we would hear from as many people as possible. We received 25 responses, primarily from large businesses and trade associations. Obviously, trade associations are often the bodies through which we hear from small and medium-sized businesses. We did as much as we could to engage as many businesses and industries as possible.
On the assessment of the impacts on industry, as I mentioned, the impact assessment was published alongside the instrument. The evidence that we collected indicated that most businesses will not have to make any significant additional changes to their activity to comply with the new requirements. We also do not expect the amendments to have a significant distributional impact, nor will they —this is important for the noble Baroness’s question—disproportionately burden small businesses. In fact, the time-limited specific exemptions will help to ensure that transition, so that it does not put too much pressure on smaller businesses.
On the post-implementation review that the noble Baroness referred to, a formal post-implementation review will commence by the end of 2031. This timing is intended to allow sufficient time for businesses to respond to the restrictions and for a number of the time-limited exemptions to have reached or approached their expiry date. That review will be supported by evidence provided through ongoing monitoring that will also take place. Additionally, as a party to the Stockholm convention, the UK is already required to undertake ongoing reporting and monitoring activities in line with our obligations under Articles 4 and 15 of the convention. This reporting and monitoring includes providing information on import and export and the use of specific exemptions. The information gathered through those processes will help inform the post-implementation review and could inform any future legislative changes that we might feel we want to bring in.
The noble Baroness, Lady Grender, asked about the revocation of the UV-328 and Dechlorane Plus bans— the things that we have already been doing. They were previously prohibited under the POPs regulations in April 2025, including specific-use exemptions as allowed by the Stockholm convention. However, we received information that indicated previously unknown continuing needs for the use of these substances in certain applications, including medical and defence applications. I hope that helps to clarify that for the noble Baroness.
That suggested that more time was needed to investigate impacts on supply chains and the transition to the alternatives. The Government therefore revoked the prohibitions on those two substances in May 2025 so that further evidence could be gathered. These issues were not confined to the UK, and other mitigations had to be implemented by other parties to the Stockholm convention. We committed at the time to reinstate the prohibitions as soon as possible, where sufficient evidence was gathered to provide greater certainty. To reassure the noble Baroness, we subsequently engaged with the relevant sectors and held a public consultation on the proposed draft legislation. We went through all the processes as we got the new information through. This instrument reinstates those prohibitions in line with the revised requirements of the Stockholm convention.